Ken Griffin Gamida Cell Ltd. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$0.04 - $0.46 $232 - $2,668	-5,800 Reduced 14.68%	33,700 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.25 - $1.02 $12,275 - $50,082	-49,100 Reduced 55.42%	39,500 $16,000
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.87 $77,095 - $169,609	-90,700 Reduced 50.59%	88,600 $91,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $93,951 - $305,019	128,700 Added 254.35%	179,300 $346,000
Q1 2023 May 15, 2023	BUY	$0.68 - $1.71 $5,440 - $13,680	8,000 Added 18.78%	50,600 $40,000
Q4 2022 Feb 14, 2023	SELL	$1.15 - $2.1 $5,979 - $10,920	-5,200 Reduced 10.88%	42,600 $54,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $46,359 - $102,717	30,300 Added 173.14%	47,800 $76,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.